HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A fully human monoclonal antibody (CR002) identifies PDGF-D as a novel mediator of mesangioproliferative glomerulonephritis.

Abstract
PDGF-B is of central importance in mesangioproliferative diseases. PDGF-D, a new PDGF isoform, like PDGF-B, signals through the PDGF betabeta-receptor. The present study first determined that PDGF-D is mitogenic for rat mesangial cells and is not inhibited by a PDGF-B antagonist. Low levels of PDGF-D mRNA were detected in normal rat glomeruli. After induction of mesangioproliferative nephritis in rats by anti-Thy 1.1 mAb, glomerular PDGF-D mRNA and protein expression increased significantly from days 4 to 9 in comparison with nonnephritic rats. Peak expression of PDGF-D mRNA occurred 2 d later than peak PDGF-B mRNA expression. In addition, PDGF-D serum levels increased significantly in the nephritic animals on day 7. For investigating the functional role of PDGF-D, neutralizing fully human mAb were generated using the XenoMouse technology. Rats with anti-Thy 1.1-induced nephritis were treated on days 3 and 5 with different amounts of a fully human PDGF-DD-specific neutralizing mAb (CR002), equal amounts of irrelevant control mAb, or PBS by intraperitoneal injection. Specific antagonism of PDGF-D led to a dose-dependent (up to 67%) reduction of glomerular cell proliferation. As judged by double immunostaining for 5-bromo-2'-deoxyuridine and alpha-smooth muscle actin, glomerular mesangial cell proliferation was reduced by up to 57%. Reduction of glomerular cell proliferation in the rats that received CR002 was not associated with reduced glomerular expression of PDGF-B mRNA. PDGF-D antagonism also led to reduced glomerular infiltration of monocytes/macrophages (day 5) and reduced accumulation of fibronectin (day 8). In contrast, no effect was noted in normal rats that received an injection of CR002. These data show that PDGF-D is overexpressed in mesangioproliferative states and can act as an auto-, para-, or even endocrine glomerular cell mitogen, indicating that antagonism of PDGF-D may represent a novel therapeutic approach to mesangioproliferative glomerulonephritides.
AuthorsTammo Ostendorf, Claudia R C van Roeyen, Jeffrey D Peterson, Uta Kunter, Frank Eitner, Avin J Hamad, Gerlinde Chan, Xiao-Chi Jia, Jennifer Macaluso, Gadi Gazit-Bornstein, Bruce A Keyt, Henri S Lichenstein, William J LaRochelle, Jürgen Floege
JournalJournal of the American Society of Nephrology : JASN (J Am Soc Nephrol) Vol. 14 Issue 9 Pg. 2237-47 (Sep 2003) ISSN: 1046-6673 [Print] United States
PMID12937299 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Monoclonal
  • Lymphokines
  • PDGFD protein, human
  • Pdgfd protein, mouse
  • Pdgfd protein, rat
  • Platelet-Derived Growth Factor
Topics
  • Animals
  • Antibodies, Monoclonal (immunology)
  • Cell Division (physiology)
  • Cells, Cultured
  • Down-Regulation
  • Glomerular Mesangium (metabolism)
  • Glomerulonephritis, Membranoproliferative (immunology, metabolism)
  • Humans
  • Lymphokines
  • Mice
  • Platelet-Derived Growth Factor (immunology, metabolism)
  • Rats
  • Up-Regulation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: